No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
478 |
4. Check minimum number of eventsNone |
478 |
5. Include endpointsNone |
478 |
6. Filter based on genotype QC (FinnGen only) |
478 |
Control definitions (FinnGen only)
- Control exclude
- G6_OTHNEU
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- G93
- Name in latin
- Laesio anoxica cerebri non alibi classificata
Similar endpoints
↥List of similar endpoints to
Anoxic brain damage
based on the number of shared cases.
Similar with more cases:
- Other neurological diseases
- Neurological diseases
- Neurological diseases, wide definition
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 7504 | 2213 | 5132 |
| Only index persons | 4082 | 1219 | 2863 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.12 | 0.06 | 0.14 |
| Only index persons | 0.09 | 0.04 | 0.11 |
| Median age at first event (years) | |||
| Whole population | 60.56 | 61.03 | 60.15 |
| Only index persons | 60.34 | 60.12 | 60.43 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 478 | 128 | 350 |
| Unadjusted period prevalence (%) | 0.12 | 0.04 | 0.15 |
| Median age at first event (years) | 62.71 | 57.89 | 64.47 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 449
- Matched controls
- 4488
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G93.1
ICD-10 Finland
Anoxic brain damage, not elsewhere classified
+∞
323.0
436
*
I46.0
ICD-10 Finland
Cardiac arrest with successful resuscitation
222.8
265.1
254
26
I49.0
ICD-10 Finland
Ventricular fibrillation and flutter
84.1
69.8
77
11
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
6.0
52.7
176
437
WX730
NOMESCO Finland
Conventional respirator
21.4
37.2
55
29
WX930
NOMESCO Finland
Thepapeutic hypothermia
+∞
32.7
31
*
AA1AD
NOMESCO Finland
CT of head and brain
3.6
28.0
159
598
WX872
NOMESCO Finland
Intensive care
7.5
27.1
67
103
I47.2
ICD-10 Finland
Ventricular tachycardia
14.2
26.3
45
35
FPG30
NOMESCO Finland
Implantation of cardioverter-defibrillator with ventricular electrode
44.2
23.9
29
7
XFP20
NOMESCO Finland
Check up of cardiac pacemaker
5.2
21.7
71
156
A98
ICPC
Health maint/preventive medicine
0.4
21.3
259
3550
XA800
NOMESCO Finland
Neuropsychological investigation
7.8
20.5
48
68
I25.1
ICD-10 Finland
Atherosclerotic heart disease
2.7
20.0
176
855
I46.9
ICD-10 Finland
Cardiac arrest, unspecified
48.3
19.4
23
5
N03AG01
ATC
valproic acid; systemic, rectal
6.3
19.0
52
92
I25.2
ICD-10 Finland
Old myocardial infarction
3.9
18.8
83
245
J69.0
ICD-10 Finland
Pneumonitis due to food and vomit
9.9
18.0
36
39
Z95.0
ICD-10 Finland
Presence of electronic cardiac devices
5.3
17.8
56
117
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
6.0
17.4
49
90
FN1AC
NOMESCO Finland
Angiography of heart and/or coronary arteries
2.5
15.5
144
701
FPG32
NOMESCO Finland
Implantation of cardioverter-defibrillator with atrial and ventricular electrodes
29.8
15.3
20
7
GBB00
NOMESCO Finland
Tracheostomy
11.4
15.2
28
26
N03AX14
ATC
levetiracetam; systemic
10.0
15.2
30
32
AN1
HP
Coronary angiography
3.0
14.7
93
357
3481A
ICD-9 Finland
Other conditions of brain, Anoxic brain damage
+∞
14.7
14
*
201
Kela drug reimbursment
Chronic cardiac insufficiency
4.0
13.5
56
155
WX900
NOMESCO Finland
Resuscitation
26.7
13.5
18
7
I42.0
ICD-10 Finland
Dilated cardiomyopathy
6.8
12.9
32
50
206
Kela drug reimbursment
Chronic coronary artery disease and dyslipidaemia associated with chronic coronary artery disease
2.3
12.9
140
728
FPJ21
NOMESCO Finland
Revision of cardioverter-defibrillator with ventricular electrode
+∞
12.6
12
*
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
4.0
12.5
51
139
Z45.0
ICD-10 Finland
Adjustment and management of cardiac devices
4.8
12.3
41
92
R4150
NOMESCO Finland
Neuropsychological rehabilitation
18.7
12.1
18
10
X44
ICD-10 Finland
Accidental poisoning by and exposure to other and unspecified drugs, medicaments and biological substances
18.7
12.1
18
10
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
2.5
12.0
104
477
WX704
NOMESCO Finland
Intubation
4.3
12.0
45
114
Z02.4
ICD-10 Finland
Examination for driving licence
0.3
11.5
28
808
G40.9
ICD-10 Finland
Epilepsy, unspecified
6.3
11.1
29
49
C09AA05
ATC
ramipril; oral
2.2
11.0
141
783
TPH07
NOMESCO Finland
Cathetrisation of artery
3.0
10.8
66
247
C07AB07
ATC
bisoprolol; oral
2.0
10.8
231
1575
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
8.5
10.4
22
27
FPG40
NOMESCO Finland
Replacement of pulse generator in transvenous cardioverter-defibrillator
33.4
10.4
13
*
AS7
HP
Arrhythmia pacemaker insertion VVI (R) S
33.4
10.4
13
*
B01AA03
ATC
warfarin; systemic
2.2
10.0
126
688
T36
ICD-10 Finland
Poisoning by systemic antibiotics
5.5
10.0
29
56
R56.8
ICD-10 Finland
Other and unspecified convulsions
4.2
9.9
37
94
C01BD01
ATC
amiodarone; systemic
5.3
9.7
29
58
C03CA01
ATC
furosemide; systemic
2.0
9.7
166
1025
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
3.4
9.5
46
146
G45.9
ICD-10 Finland
Transient cerebral ischaemic attack, unspecified
18.0
9.5
14
8
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
8.3
9.4
20
25
PH1AC
NOMESCO Finland
Flebography of over extremity with X-ray
12.7
9.4
16
13
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.0
9.4
142
836
X69
ICD-10 Finland
Intentional self-poisoning by and exposure to other and unspecified chemicals and noxious substances
6.3
9.0
23
38
I50.1
ICD-10 Finland
Left ventricular failure
3.7
9.0
39
113
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
8.2
8.9
19
24
F32.9
ICD-10 Finland
Depressive episode, unspecified
2.9
8.5
52
193
I50.0
ICD-10 Finland
Congestive heart failure
2.8
8.3
55
216
M01AH05
ATC
etoricoxib; oral
0.5
8.2
107
1675
WX882
NOMESCO Finland
High dependency care
4.8
8.1
26
57
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
3.0
8.1
46
163
N05AX08
ATC
risperidone; systemic
2.9
8.1
48
177
UGC12
NOMESCO Finland
Flexible bronchoscopy
2.8
8.0
53
207
112
Kela drug reimbursment
Severe psychotic and other severe mental disorders
3.1
7.9
44
154
G41.9
ICD-10 Finland
Status epilepticus, unspecified
15.4
7.7
12
8
W79
ICD-10 Finland
Inhalation and ingestion of food causing obstruction of respiratory tract
45.8
7.7
9
*
X70
ICD-10 Finland
Intentional self-harm by hanging, strangulation and suffocation
45.8
7.7
9
*
XA400
NOMESCO Finland
EEG
45.8
7.7
9
*
183
Kela drug reimbursment
Lamotrigin and topiramate
18.7
7.6
11
6
R1230
NOMESCO Finland
Neuropsychological evaluation of need and possibilities to rehabilitation
9.1
7.6
15
17
I20.81
ICD-10 Finland
Other angina pectoris stenosed coronary artery
2.5
7.4
59
257
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.1
7.4
86
450
G93.0
ICD-10 Finland
Cerebral cysts
+∞
7.3
7
*
I21.00
ICD-10 Finland
Acute transmural myocardial infarction of anterior wall
5.6
7.3
20
37
F60.9
ICD-10 Finland
Personality disorder, unspecified
16.1
7.3
11
7
I25.9
ICD-10 Finland
Chronic ischaemic heart disease, unspecified
2.2
7.1
72
354
WX890
NOMESCO Finland
Intesive care monitoring
9.0
7.1
14
16
C01DA02
ATC
glyceryl trinitrate; oral, oral aerosol, sublingual, transdermal
1.9
6.8
122
750
G45.1
ICD-10 Finland
Carotid artery syndrome (hemispheric)
40.7
6.8
8
*
FPG96
NOMESCO Finland
Other implantation of permanent cardioverter-defibrillator
17.0
6.8
10
6
I21.01
ICD-10 Finland
Acute transmural myocardial infarction of anterior wall
5.1
6.7
20
41
N29
ICPC
Neurological sympt/complt other
6.6
6.7
16
25
F32.2
ICD-10 Finland
Severe depressive episode without psychotic symptoms
3.5
6.7
29
86
I21.09
ICD-10 Finland
Acute transmural myocardial infarction of anterior wall
5.5
6.5
18
34
R40.2
ICD-10 Finland
Coma, unspecified
8.3
6.4
13
16
FNA01
NOMESCO Finland
Anastomosis to coronary artery from internal mammary artery, one distal anastamosis
2.9
6.3
36
129
XF409
NOMESCO Finland
Other special ECG
18.3
6.3
9
5
Z95.1
ICD-10 Finland
Presence of aortocoronary bypass graft
2.9
6.3
36
130
FPJ22
NOMESCO Finland
Revision of cardioverter-defibrillator with atrial and ventricular electrodes
+∞
6.3
6
*
G91.1
ICD-10 Finland
Obstructive hydrocephalus
+∞
6.3
6
*
G93.2
ICD-10 Finland
Benign intracranial hypertension
+∞
6.3
6
*
L89
ICD-10 Finland
Decubitus ulcer and pressure area
5.2
6.2
18
36
R55
ICD-10 Finland
Syncope and collapse
2.3
6.2
57
266
N18
ICPC
Paralysis/weakness
5.5
6.2
17
32
I50.9
ICD-10 Finland
Heart failure, unspecified
2.0
6.1
83
461
289
Kela drug reimbursment
Combination product containing sacubitril and valsartan
12.7
6.1
10
8
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
2.3
6.1
54
250
N05AH03
ATC
olanzapine; systemic
3.3
6.1
29
93
E10.00
ICD-10 Finland
Insulin-dependent diabetes diabetic hypoglycemic coma
10.2
6.1
11
11
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.0
6.0
75
402
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
293
3928
0.34
26.83
34.7
23.0
131.2
135.9
g/l
4.67
287
3854
293
3926
0.34
26.69
34.5
22.8
4.3
4.5
e12/l
5.42
280
3798
293
3924
0.35
26.55
34.6
22.9
232.4
239.0
e9/l
0.89
279
3812
98
342
3.35
22.65
8.8
8.2
9.0
10.9
mmol/l
1.63
91
323
247
3494
0.39
21.96
5.4
5.0
2.4
2.6
mmol/l
4.99
229
3167
236
3386
0.40
21.15
4.8
4.5
1.3
1.4
mmol/l
0.61
222
3072
230
3305
0.41
19.80
20.9
14.9
81.0
78.1
ml/min/173m2
0.85
195
2759
285
3753
0.40
19.74
13.4
10.7
35.2
27.2
u/l
1.42
275
3611
244
3415
0.42
19.41
5.0
4.5
4.2
4.5
mmol/l
3.32
226
3127
244
3409
0.42
19.14
4.9
4.6
6.2
6.1
mmol/l
0.36
221
3061
231
3274
0.43
18.12
6.8
6.1
41.1
40.7
mmol/mol
0.26
219
3014
235
3294
0.44
17.53
4.6
4.0
1.4
1.3
mmol/l
0.44
218
2976
225
3203
0.44
17.38
28.7
17.1
38.9
39.7
%
0.52
138
2222
290
3687
0.46
14.69
32.3
18.7
4.0
4.0
mmol/l
0.10
281
3571
291
3677
0.47
13.93
32.8
18.5
138.9
139.7
mmol/l
2.77
285
3566
46
1159
0.33
12.21
2.6
3.0
0.6
0.8
ug/l
1.40
34
773
121
2024
0.46
12.14
2.6
2.8
—
—
—
0
0
232
3105
0.51
11.78
5.3
4.2
2.2
2.0
mu/l
0.69
215
2761
119
1984
0.47
11.65
3.7
5.2
2.0
3.7
ug/l
1.94
101
1745
94
453
2.34
11.22
12.9
8.9
0.4
1.2
mmol/l
0.80
71
345
287
3571
0.51
11.17
24.8
15.7
31.1
26.8
mg/l
1.25
246
2886
33
92
3.78
10.55
1.6
3.6
36.8
34.3
umol/l
0.13
26
77
186
2626
0.52
10.53
4.1
4.0
13.8
13.2
mm/h
0.17
176
2389
92
452
2.28
10.45
13.7
8.9
5.3
5.1
kpa
0.51
86
425
92
452
2.28
10.45
13.7
8.9
13.1
11.3
kpa
1.54
85
428
111
600
2.11
9.91
5.8
3.6
0.9
0.8
mmol/l
0.88
104
558
96
493
2.19
9.76
7.5
6.2
1.1
1.0
mmol/l
1.82
89
451
91
1588
0.47
9.50
4.1
4.4
22.0
21.4
%
0.14
38
779
71
343
2.26
8.32
3.4
2.7
25.7
7.5
ug/l
2.00
65
303
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
34
135
2.63
6.09
3.6
2.6
0.3
0.3
u/ml
0.21
21
79
40
178
2.36
5.66
2.6
2.0
0.9
1.7
ug/l
0.70
35
154
52
262
2.10
5.47
2.0
1.6
—
—
—
0
0
84
534
1.70
4.33
34.1
28.4
1.5
1.3
inr
0.56
14
75
124
1678
0.65
4.15
5.4
5.1
0.0
0.0
estimate
0.00
26
328
59
347
1.80
3.98
5.3
2.9
241.6
252.1
ng/l
0.08
54
314
142
1049
1.50
3.85
2.8
2.2
332.1
350.1
u/l
0.06
133
983
111
1516
0.65
3.80
2.4
2.0
101.1
92.1
pmol/l
1.21
63
833
187
2307
0.69
3.78
4.4
3.3
74.3
54.8
u/l
1.76
165
2147
129
1704
0.67
3.73
4.3
3.7
0.0
0.0
estimate
0.00
26
309
129
1699
0.67
3.66
4.3
3.6
0.0
0.0
estimate
0.00
27
322
237
2791
0.70
3.61
9.2
7.9
84.0
80.9
u/l
0.34
229
2611
203
2455
0.70
3.60
4.3
3.5
15.0
14.8
pmol/l
0.46
185
2180
68
1016
0.61
3.44
3.1
2.9
372.1
7493.7
umol/l
4.18
56
870
8
14
5.79
3.35
3.1
4.8
78.9
110.7
%
—
8
14
165
2050
0.70
3.31
10.1
9.3
4.6
4.2
e9/l
1.27
153
1798
63
938
0.62
3.11
1.6
1.6
22.6
19.8
nmol/l
0.67
56
800
27
504
0.51
3.03
1.7
1.4
—
—
—
0
0
196
2338
0.73
2.94
4.7
4.4
127.6
1978.9
e6/l
—
5
44
28
510
0.52
2.91
1.2
1.2
1.4
11.3
u/ml
—
10
196
117
1507
0.70
2.76
3.6
2.7
165.9
162.3
ug/l
0.06
104
1378
29
513
0.54
2.74
1.3
1.3
20.7
39.3
iu/ml
—
9
167
44
683
0.61
2.57
2.9
2.9
0.7
0.9
e6/l
0.57
26
413
42
650
0.61
2.42
2.8
3.1
1.0
1.4
e6/l
0.42
24
383
65
913
0.67
2.41
1.8
1.7
1.4
1.4
mmol/l
0.05
60
763
44
670
0.62
2.37
1.3
1.3
0.7
1.7
u/ml
—
9
163
104
1328
0.72
2.25
4.4
3.8
—
—
—
0
0
84
1097
0.72
2.07
3.7
3.3
0.9
0.5
e6/l
0.37
70
833
28
163
1.76
2.03
3.7
3.5
4.1
4.5
pmol/l
1.16
23
140
13
58
2.28
1.92
3.5
1.7
145.9
390.2
u/l
—
6
16
96
1199
0.75
1.74
3.8
4.1
15.7
11.9
mg/mmol
0.22
73
809
7
27
2.62
1.52
1.4
1.8
—
—
—
0
0
9
37
2.46
1.48
2.1
2.8
—
—
—
0
0
9
41
2.22
1.37
1.1
1.2
—
—
—
0
0
19
112
1.73
1.37
1.4
1.2
—
—
—
0
0
89
719
1.29
1.34
6.2
3.8
2385.4
336.5
ng/l
0.80
79
585
115
1359
0.80
1.32
2.4
2.2
71.6
76.1
nmol/l
1.08
100
1208
13
69
1.91
1.29
1.5
1.2
430.4
474.1
mg/l
0.22
13
63
53
684
0.75
1.21
4.8
3.2
2.4
2.4
mmol/l
0.02
41
600
5
111
0.44
1.14
1.6
1.9
—
—
—
0
0
5
21
2.40
1.09
1.4
1.9
—
—
—
0
0
17
265
0.63
1.08
1.5
1.7
—
—
—
0
0
141
1233
1.20
1.05
4.6
3.2
2604.1
1914.7
ng/l
0.64
131
1064
5
22
2.29
1.03
1.4
1.9
—
—
—
0
0
11
60
1.85
1.03
1.3
1.3
1.7
9.2
e6/l
0.88
11
47
11
60
1.85
1.03
1.4
1.4
13.5
1982.9
e6/l
0.56
11
49
46
353
1.34
1.02
3.1
2.5
0.2
0.2
g/l
0.28
40
327
9
48
1.89
1.01
1.3
1.8
—
—
—
0
0
11
61
1.82
0.99
1.4
1.1
3.8
3.7
mmol/l
0.18
11
56
121
1384
0.83
0.98
3.6
3.3
—
—
—
0
0
0
30
0.00
0.97
0.0
1.2
—
—
—
0
0
48
374
1.32
0.97
9.5
4.2
1.2
1.9
mmol/l
0.93
36
295
27
192
1.43
0.94
11.0
3.4
24.0
25.3
mmol/l
1.32
27
186
12
72
1.68
0.86
2.4
3.3
5.4
4.7
e9/l
0.25
12
72
165
1493
1.16
0.81
4.8
3.9
98.1
48.8
ng/l
2.16
139
1092
129
1149
1.17
0.77
3.3
2.6
75.1
56.6
u/l
0.58
121
1067
12
75
1.62
0.75
2.7
3.9
60.5
57.5
%
0.29
12
75
15
100
1.52
0.73
1.2
1.6
—
—
—
0
0
9
56
1.62
0.72
1.3
1.6
—
—
—
0
0
7
40
1.76
0.71
1.0
1.6
—
—
—
0
0
9
57
1.59
0.71
1.3
1.7
—
—
—
0
0
130
1172
1.15
0.67
3.6
3.6
153.4
33.9
u/l
0.83
123
1112
10
62
1.63
0.65
2.0
3.4
—
972.8
—
0
6
10
153
0.65
0.63
1.1
1.0
—
—
—
0
0
80
912
0.85
0.63
4.5
3.8
0.0
0.0
estimate
0.50
25
310
65
752
0.84
0.61
5.3
3.9
1.0
1.0
kg/l
1.01
11
105
0
21
0.00
0.60
0.0
3.5
—
81.8
—
0
21
14
97
1.46
0.59
1.2
1.6
—
—
—
0
0
29
229
1.28
0.58
1.9
1.4
—
—
—
0
0
7
116
0.60
0.58
1.9
1.6
46.7
41.6
nmol/l
—
7
109
48
403
1.21
0.58
6.5
3.7
—
—
—
0
0
40
480
0.82
0.56
2.1
3.9
312.1
253.9
u/l
1.09
35
450
6
37
1.63
0.55
1.0
1.7
—
—
—
0
0
46
387
1.21
0.55
2.2
1.9
1.9
1.6
%
1.39
40
338
10
66
1.53
0.53
1.3
1.5
—
—
—
0
0
33
401
0.81
0.52
2.8
4.5
5.1
38.8
ug/l
1.03
26
335
6
100
0.59
0.52
1.3
1.6
—
—
—
0
0
11
75
1.48
0.51
1.3
1.6
—
—
—
0
0
10
68
1.48
0.47
1.3
1.6
—
—
—
0
0
5
84
0.59
0.46
3.6
1.7
234.0
230.4
pmol/l
—
5
78
33
275
1.21
0.45
3.0
3.1
65.1
64.5
ml/min/173m2
0.04
22
118
204
1932
1.10
0.44
7.3
6.7
13.4
12.2
umol/l
0.24
194
1828
92
1009
0.89
0.43
2.8
2.1
3.3
3.1
mg/l
0.32
74
860
6
92
0.65
0.42
1.5
1.5
—
—
—
0
0
10
139
0.71
0.42
3.1
3.1
—
—
—
0
0
35
296
1.20
0.42
5.1
3.7
1.2
1.2
mmol/l
1.15
29
263
0
15
0.00
0.41
0.0
1.1
—
8.2
—
0
15
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.2
—
—
—
0
0
0
17
0.00
0.40
0.0
1.0
—
—
—
0
0
0
17
0.00
0.40
0.0
1.1
—
—
—
0
0
0
17
0.00
0.40
0.0
1.1
—
—
—
0
0
5
34
1.48
0.40
1.0
1.5
—
—
—
0
0
5
34
1.48
0.40
1.0
1.5
—
—
—
0
0
5
34
1.48
0.40
1.0
1.5
—
—
—
0
0
0
18
0.00
0.40
0.0
2.1
—
—
—
0
0
20
160
1.26
0.39
2.2
2.9
—
—
—
0
0
38
440
0.85
0.39
13.7
6.9
—
—
—
0
0
168
1587
1.09
0.38
7.1
5.1
33.1
35.1
g/l
3.05
150
1482
5
37
1.35
0.37
1.6
1.6
—
—
—
0
0
83
758
1.11
0.37
1.8
1.7
1225.2
1114.2
nmol/l
0.61
65
577
24
288
0.82
0.36
1.5
1.4
—
—
—
0
0
11
81
1.37
0.36
1.0
1.1
—
3.3
—
0
8
13
101
1.30
0.32
1.4
2.0
—
—
—
0
0
113
1205
0.92
0.31
4.3
3.5
2.3
2.3
mmol/l
0.10
103
1054
7
53
1.33
0.31
1.4
1.7
—
—
—
0
0
7
100
0.70
0.31
1.1
1.2
—
—
—
0
0
7
100
0.70
0.31
1.1
1.2
—
—
—
0
0
13
104
1.26
0.26
1.5
1.3
—
—
—
0
0
15
123
1.23
0.25
1.6
2.1
—
—
—
0
0
85
795
1.08
0.25
1.6
1.8
445.3
8584752.6
pmol/l
0.50
72
664
5
41
1.22
0.22
1.2
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
10
80
1.26
0.20
1.6
1.4
—
—
—
0
0
13
155
0.83
0.20
1.2
1.3
—
—
—
0
0
0
14
0.00
0.20
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.5
—
—
—
0
0
9
111
0.81
0.20
2.1
1.5
—
—
—
0
0
59
632
0.92
0.20
3.8
2.5
11.4
12.7
umol/l
0.84
53
584
6
53
1.13
0.18
1.0
1.2
—
—
—
0
0
71
675
1.06
0.15
1.9
1.9
—
—
—
0
0
42
449
0.93
0.14
3.3
3.3
7.3
8.6
umol/l
0.43
34
400
19
170
1.12
0.13
1.7
1.9
—
—
—
0
0
50
474
1.06
0.12
2.0
1.8
—
—
—
0
0
27
250
1.08
0.11
1.7
1.8
—
—
—
0
0
168
1645
1.03
0.10
15.1
6.5
1.2
1.2
mmol/l
4.44
153
1482
166
1695
0.97
0.10
4.9
4.2
—
—
—
0
0
30
280
1.08
0.10
8.9
3.9
2.8
1.9
mmol/l
0.75
22
209
11
125
0.88
0.10
3.5
4.0
48.5
113.7
mg/l
—
6
101
60
577
1.05
0.09
3.7
2.4
2.3
2.3
g/l
0.07
52
532
5
62
0.80
0.08
1.2
1.4
—
—
—
0
0
5
62
0.80
0.08
1.2
1.1
—
—
—
0
0
32
338
0.94
0.08
2.4
2.6
37.8
34.9
u/l
0.21
25
290
49
470
1.05
0.08
2.0
1.8
—
—
—
0
0
11
123
0.89
0.08
3.2
3.9
—
2.6
—
0
11
221
2181
1.02
0.08
10.8
5.1
7.0
6.9
mmol/l
0.19
208
2043
6
71
0.84
0.07
1.0
1.3
—
—
—
0
0
7
82
0.85
0.07
1.6
1.4
—
—
—
0
0
7
85
0.82
0.07
1.4
1.2
—
—
—
0
0
7
85
0.82
0.07
1.4
1.2
—
—
—
0
0
9
86
1.05
0.07
1.0
1.4
—
—
—
0
0
56
545
1.03
0.05
4.1
2.5
20.5
22.9
%
0.73
46
464
76
772
0.98
0.03
2.0
1.7
2.0
1.4
mg/l
0.65
60
598
182
1812
1.01
0.01
13.0
7.2
1.2
1.2
mmol/l
3.38
150
1521
12
114
1.05
0.00
1.8
1.5
—
—
—
0
0
28
274
1.02
0.00
1.8
2.0
—
—
—
0
0
16
156
1.03
0.00
1.8
1.8
—
—
—
0
0
17
169
1.01
0.00
1.1
1.2
120.2
172.4
iu/ml
—
6
55
88
881
1.00
0.00
3.0
2.4
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
9
97
0.93
0.00
4.2
2.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
9.6
—
31.2
—
0
5
5
51
0.98
0.00
2.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
21.6
—
0
8
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.8
—
—
—
0
0
5
50
1.00
0.00
2.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
5.7
—
—
—
0
0
5
52
0.96
0.00
2.0
1.4
—
—
—
0
0
5
52
0.96
0.00
2.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
5
52
0.96
0.00
2.0
1.4
—
—
—
0
0
6
63
0.95
0.00
1.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
5
52
0.96
0.00
2.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
6
60
1.00
0.00
3.5
2.4
3.8
4.2
u/ml
—
6
55
7
73
0.96
0.00
2.4
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint G6_ANOXBRAINDAM and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_ANOXBRAINDAM | 5.632 [4.28, 7.42] | < 0.001 |
| Birth year | 0.998 [0.99, 1.01] | 0.638 |
During the follow-up period (1.1.1998 — 31.12.2019), 257 out of 594 females with G6_ANOXBRAINDAM died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_ANOXBRAINDAM | 4.447 [3.79, 5.22] | < 0.001 |
| Birth year | 0.992 [0.98, 1.0] | 0.062 |
During the follow-up period (1.1.1998 — 31.12.2019), 781 out of 1580 males with G6_ANOXBRAINDAM died.
Mortality risk
Mortality risk for people of age
years, who have G6_ANOXBRAINDAM.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.472% | 1.023% |
| 5 | 3.401% | 5.482% |
| 10 | 9.156% | 13.608% |
| 15 | 16.581% | 24.711% |
| 20 | 27.016% | 40.035% |
Relationships between endpoints
↥Index endpoint: G6_ANOXBRAINDAM – Anoxic brain damage
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data